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Summary Background This trial evaluated the maximum
tolerated dose (MTD), safety, pharmacokinetics, and activity
of volasertib, a selective Polo-like kinase 1 inhibitor that in-
duces mitotic arrest and apoptosis, combined with cisplatin or
carboplatin in patients with advanced/metastatic solid tumors
(NCT00969761; 1230.6).Methods Sequential patient cohorts
(3+3 dose-escalation design) received a single infusion of
volasertib (100–350 mg) with cisplatin (60–100 mg/m2) or
carboplatin (area under the concentration versus time curve
[AUC]4–AUC6) on day 1 every 3 weeks for up to six cycles.
Sixty-one patients received volasertib/cisplatin (n=30) or
volasertib/carboplatin (n=31) for a median of 3.5 (range, 1–6)
and 2.0 (range, 1–6) treatment cycles, respectively. Results
The most common cycle 1 dose-limiting toxicities (DLTs)
were thrombocytopenia, neutropenia and fatigue. MTDs
(based on cycle 1 DLTs) were determined to be volasertib
300 mg plus cisplatin 100 mg/m2 and volasertib 300 mg plus
carboplatin AUC6. Co-administration did not affect the phar-
macokinetics of each drug. Partial responses were observed in
two patients in each arm. Stable disease was achieved in 11
and six patients treated with volasertib/cisplatin and
volasertib/carboplatin, respectively. Conclusions Volasertib
plus cisplatin or carboplatin at full single-agent doses was
generally manageable and demonstrated activity in heavily
pretreated patients with advanced solid tumors.
Keywords Polo-like kinase inhibitor . Solid tumors . Phase I
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Introduction
Most advanced or metastatic solid tumors are incurable de-
spite the availability of multiple treatment modalities such as
surgery, cytotoxic drugs, radiation therapy, and combinations
of these therapies. Response to treatment in the advanced set-
ting is dependent on the tumor type and treatment modality;
however, these responses are rarely long lasting and are often
followed by tumor progression and subsequently death. Novel
treatment approaches are therefore required.
Polo-like kinase (Plk) 1 is a key enzyme regulating essen-
tial steps of mitosis including mitotic entry, centrosome mat-
uration and separation, formation of the bipolar spindle,
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transition from metaphase to anaphase, and initiation of cyto-
kinesis [1,2]. The functional relevance of Plk1 has been dem-
onstrated in vitro by ‘knock-down’ experiments in cancer cell
lines. In these experiments, depletion of Plk1 was accompa-
nied by cell cycle arrest and apoptosis [3–6]. Overexpression
of Plk1 has been observed in multiple human cancers [6–10]
and has been associated with poor prognosis [11]. These find-
ings suggest that Plk1 may be a promising target in cancer.
Volasertib, an investigational agent, is a potent and
selective cell cycle kinase inhibitor that induces mitotic
arrest and apoptosis by targeting Plk at low nanomolar
concentrations [12]. Volasertib selectively inhibits Plk1 and,
to a lesser extent, two other members of the Plk family,
Plk2 and Plk3, but does not inhibit unrelated kinases (>50
other kinases) at concentrations up to 10 μM [12].
Compared with BI 2536 (the first Plk inhibitor to be
developed by Boehringer Ingelheim), volasertib showed a
high volume of distribution, indicating good tissue penetra-
tion, and a long terminal half-life (t1/2) in preclinical
studies [12]. As a result, clinical investigation of BI
2536 was halted and clinical development continued with
volasertib. Early clinical data has indicated that the adverse
event (AE) profile of volasertib is generally manageable
and that volasertib may have antitumor activity. In a
phase I study, reversible hematologic AEs (neutropenia,
thrombocytopenia) constituted the dose-limiting toxicities
(DLTs) in patients with progressive advanced or metastatic
solid tumors who received single-agent volasertib. The
maximum tolerated dose (MTD) was 400 mg; however,
300 mg was considered to be the recommended dose for
further clinical investigation based on overall tolerability.
Encouraging signs of antitumor activity were seen in three
patients with confirmed partial response (PR) of lesions in
urothelial cancer, ovarian cancer, or melanoma, and 40 % of
patients experienced stable disease (SD) [13].
Although antineoplastic platinum agents like cisplatin
and carboplatin have already exhibited promising results
in clinical trials, many patients are refractory or relapse
quickly after treatment. Preclinical data show that the
combination of BI 2536 with cisplatin may confer synergism
versus either therapy alone [14], which may be the result of a
sensitization to cisplatin with Plk1 suppression [15]. The
combination of BI 2536 and cisplatin resulted in improved
efficacy in both in vitro and murine xenograft models
compared with cisplatin alone [16]. A similar synergistic
effect has also been observed following Plk1 downregulation
in combination with carboplatin treatment in preclinical
studies [17].
This phase I, dose-escalation study was conducted to de-
termine the MTD of volasertib in combination with cisplatin
or carboplatin and to evaluate the safety and activity of this
combination in patients with advanced or metastatic solid
tumors.
Material and methods
Trial design
This was a phase I, open-label, parallel-group, 3+3 dose-
escalation trial of combination therapy with volasertib and
cisplatin, or volasertib and carboplatin, conducted at two cen-
ters in Belgium (ClinicalTrials.gov ID: NCT00969761;
1230.6). The primary endpoint was determination of the
MTD, defined as the highest dose of volasertib in combination
with cisplatin or carboplatin at which the incidence of DLTs
during the first cycle was less than 33 % (i.e., fewer than two
of six patients). Secondary endpoints included pharmacoki-
netics and evaluation of overall safety and antitumor activity.
Safety endpoints included the incidence and intensity of AEs,
DLTs, serious and significant AEs, laboratory parameters, and
vital signs. Efficacy endpoints included overall response rate,
duration of objective response, rate and duration of disease
control, and progression-free survival (PFS).
Patient selection
Patients aged ≥18 years with confirmed diagnosis of ad-
vanced, non-resectable or metastatic solid tumors, who had
failed conventional treatment, or for whom no therapy of
proven efficacy existed, or who were not amenable to
established forms of treatment, were eligible for this trial.
Additional inclusion criteria were: indication for treatment
with platinum therapy as judged by the investigator; Eastern
Cooperative Oncology Group Performance Status (ECOG PS)
≤2; and recovery from Common Terminology Criteria for
Adverse Events (CTCAE) grade 2 to 4 therapy-related AEs
from previous systemic anticancer therapies or radiotherapies
(except alopecia of CTCAE grade 2). Patients were excluded
if they had clinical evidence of symptomatic progressive brain
or leptomeningeal disease during the past 6 months; second
malignancy currently requiring another anticancer therapy;
absolute neutrophil count (ANC) <1,500/mm3; platelet count
<100,000/mm3; serum creatinine >1.5 mg/dL (>132 μM/L, SI
unit equivalent) or creatinine clearance <70 mL/min (as cal-
culated according to Cockcroft–Gault formula for glomerular
filtration rate [GFR] estimate); known history of relevant QT
prolongation, (e.g., longQTsyndrome); pre-existing clinically
relevant hearing loss; treatment with other investigational
drugs or participation in another clinical interventional trial
within the 4 weeks prior to the start of therapy or concomi-
tantly with this trial, or systemic anticancer therapy or radio-
therapy within the 4 weeks prior to the start of therapy or
concomitantly with this trial, with the exception of steroids
and bisphosphonates. The study was conducted in accordance
with the ethical principles originating from the Declaration of
Helsinki and Good Clinical Practice as defined by the
International Conference on Harmonization. The study was
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approved by the local Independent Ethics Committees and/or
Institutional Review Boards of the participating centers and
the Federal Agency for Medicines and Health Products,
Brussels, Belgium. All participating patients gave written in-
formed consent.
Treatment
Volasertib was administered as a single dose by intravenous
infusion over 2 hours, starting in the first treatment cycle, on
day 1 every 3 weeks, given 30 minutes after a 1-hour intrave-
nous cisplatin infusion on day 1 of a 3-week cycle or a 1-hour
intravenous carboplatin infusion on day 1 of a 3-week cycle
(Fig. S1 [Online Resource 1]). The starting doses for each
platinum combination were volasertib 100 mg combined with
cisplatin 60mg/m2 or carboplatin area under the concentration
versus time curve (AUC)4. Subsequent dose cohorts are listed
in Table S1 (Online Resource 2). Target doses for carboplatin
were calculated using the Calvert formula [18] to achieve
AUC4, AUC5, and AUC6: dose (mg)= target AUC x
(GFR+25); GFR=(140 – age [years]) x (actual weight [kg])/
(72 x serum creatinine [mg/dL]); multiplied by another factor
of 0.85 if female. The maximum absolute dose of carboplatin
per cycle was limited to 900 mg, as recommended by the US
Food and Drug Administration [19].
Dose escalation of volasertib followed a 3+3 design,
whereby cohorts of three to six patients were entered sequen-
tially. The first patient of each dosage cohort was treated and
observed until day 15 before the remaining two patients were
entered. The decision regarding dose escalation was based on
the occurrence of DLTs during the first treatment cycle. After
determination of the MTD, patient enrollment at higher dos-
age tiers was suspended. Up to 12 patients could be treated at
the MTD. This volasertib dose-escalation scheme was applied
to each platinum combination. Volasertib plus cisplatin or
carboplatin were given for up to six cycles; volasertib mono-
therapy was continued after six cycles of combination therapy
until progression or intolerance. Dose reductions were permit-
ted for patients with DLTs. Upon development of a DLT, study
treatment was stopped temporarily and could be resumed
(after recovery, with a maximum of 35 days between
two dose administrations) at a reduced dose according to
prespecified dose-reduction schemes for non-hematologic and
hematologic AEs.
Assessments
All patients were monitored carefully for AEs during and after
treatment until discontinuation from trial. AEs were docu-
mented and graded according to CTCAE version 3.0 and
assessed for relatedness to the combination treatment. DLTs
were defined as any of the following AEs: drug-related grade 3
or 4 non-hematologic AEs (except ototoxicity and vomiting
or diarrhea responding to supportive treatment); drug-related
grade 4 neutropenia lasting ≥7 days and/or complicated
by infection; grade 4 thrombocytopenia; or drug-related
grade 3 febrile neutropenia (ANC <1,000/mm3 and fever
≥38.5 °C).
Blood was collected at specified time points during the first
and second cycles of each treatment schedule for pharmaco-
kinetic analyses to determine the plasma concentration of
volasertib and/or total platinum. Plasma concentrations
in cycle 1 were determined before the start of platinum infusions
(–1 hour 35 minutes relative to the start of the volasertib infu-
sion), shortly before the end of platinum infusion (–30 minutes),
during volasertib infusion (1 hour), immediately before the end
of volasertib infusion (2 hours), and at 3, 8, 24, 48, 168, and
336 hours after the start of volasertib infusion. The plasma
concentrations in cycle 2 were determined before the start of
platinum infusions (–1 hour 35 minutes), shortly before end
of platinum infusion (–30 minutes), and immediately before
the end of volasertib infusion (2 hours). Plasma concentrations
of both volasertib and CD 10899, the predominant circulating
hydroxylated metabolite of volasertib previously identified in
early clinical studies of volasertib metabolism in cancer
patients [13], were determined simultaneously by validated
high performance liquid chromatography-tandem mass
spectrometry (HPLC-MS/MS) assay using [D3]volasertib
and [D3]CD 10899 as internal standards. The samples
were subjected to solid-phase extraction in a 96-well plate
format. Chromatography was achieved on an analytical
reversed-phase HPLC column with gradient elution. The
substances were detected and quantified by HPLC-MS/
MS using electrospray ionization in the positive ion mode.
Assay performance during the study was assessed by
back-calculation of calibration standards, tabulation of the
standard curve fit function parameters and measurement of
quality control samples. No relevant interference of endogenous
compounds was observed in human plasma samples.
The calibration curves were linear over the range of
concentrations from 0.200 to 200 ng/mL volasertib base
salt (BS) and CD 10899 BS using a plasma volume of
50 μL. Plasma concentrations of cisplatin and carboplatin
were determined as total platinum by inductively coupled
plasma-mass spectrometry (ICP-MS) using 175Lu (lutetium)
as an internal standard. Samples were diluted and acidified
prior to analysis and were introduced into the ICP-MS
system without further sample preparation. The ions
were separated and detected in the mass spectrometer
and the peak areas of platinum and lutetium were
determined.
Tumor measurements were performed at screening and at the
end of every other treatment cycle by computed tomography or
magnetic resonance imaging. Overall response was assessed
according to Response Evaluation Criteria In Solid Tumors
(RECIST; version 1.1) [20].
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Statistical analysis
This was an open-label study and all analyses were descriptive
and exploratory. The analysis population was the treated set
that consisted of all patients who received ≥1 administration of
volasertib with cisplatin or carboplatin. The analysis of the
primary endpoint, determination of the MTD, was performed
on the basis of DLT observed during the first cycle, per dose
cohort. The treated set was used for tumor response and phar-
macokinetic analyses.
Results
Patient demographics and disposition
In total, 61 patients received volasertib in combination with
either cisplatin (n=30) or carboplatin (n=31). Patient demo-
graphics are shown in Table 1. In the volasertib/cisplatin arm,
the median age (range) was 55 (17–77) years and 53.3 % were
male. All patients had an ECOG PS of 0 (43.3 %) or 1
(56.7 %). Four of 30 patients (13.3 %) in the volasertib/
cisplatin arm discontinued the trial before starting cycle 2
(progressive disease [PD], n=2 [6.7 %]; DLT, n=1 [3.3 %];
other AE [neoplasm progression], n=1 [3.3 %]). Twenty-six
patients (86.7 %) received at least two cycles of combination
treatment. Of these 26 patients, two patients (7.7 %)
discontinued the trial because of other AEs, while 24 patients
(92.3 %) continued their treatment until PD.
In the volasertib/carboplatin arm, the median age (range)
was 58 (23–81) years and 58.1 % were male. All patients had
an ECOG PS of 0 (45.2 %) or 1 (54.8 %). Three out of 31
patients (9.7%) in the volasertib/carboplatin arm discontinued
the trial before starting cycle 2 (PD, n=2 [6.5 %]; refusal to
continue receiving trial medication, n=1 [3.2 %]). Twenty-
eight patients (90.3 %) received at least two cycles of combi-
nation treatment. Of these 28 patients, three patients (10.7 %)
discontinued the trial because of other AEs, while 25 patients
(89.3 %) continued their treatment until PD.
Treatment exposure
In the volasertib/cisplatin arm, the median (range) number of
treatment cycles of volasertib administered overall was 3.5
(1–20), with a total absolute dose exposure to volasertib
across the cohorts of 675.0 (200–4,400) mg. The median
(range) number of treatment cycles of cisplatin in combination
with volasertib administered overall was 3.5 (1–6) and the
median (range) total absolute dose exposure to cisplatin
across the cohorts was 440.5 (130–1,200) mg.
In the volasertib/carboplatin arm, the median (range) num-
ber of treatment cycles of volasertib administered overall was
2.0 (1–14), with a total absolute dose exposure to volasertib
across the cohorts of 600.0 (200–3,300)mg. Themedian num-
ber (range) of treatment cycles of carboplatin in combination
with volasertib administered overall was 2.0 (1–6) and the
median (range) total absolute dose exposure to carboplatin
across the cohorts was 1647.0 (426–4,382) mg.
Primary endpoint: determination of MTD assessed by DLTs
in cycle 1
In the volasertib/cisplatin arm, no DLTs were observed during
the first treatment cycle in the first four cohorts tested
(volasertib/cisplatin: 100/60, 100/75, 200/75 and 300/75;
Table 2). One of six patients in the 300/100 cohort experi-
enced a DLT during cycle 1 (grade 4 neutropenia for ≥7 days).
Dose escalation to 350/75 resulted in two of six patients
experiencing a DLT during cycle 1 (grade 3 increased alanine
aminotransferase [ALT; n=1]; grade 3 fatigue and grade 4
neutropenia for ≥7 days [n=1]). As there were two patients
Table 1 Patient demographics and baseline characteristics (treated set)
Volasertib/cisplatin
(n=30)
Volasertib/carboplatin
(n=31)
Age, median (range), years 55 (17–77) 58 (23–81)
Male/female, n (%) 16 (53.3)/14 (46.7) 18 (58.1)/13 (41.9)
Baseline ECOG PS, n (%)
0 13 (43.3) 14 (45.2)
1 17 (56.7) 17 (54.8)
Stage at diagnosis, n (%)
0 0 (0.0) 1 (3.2)
I 1 (3.3) 3 (9.7)
II 1 (3.3) 3 (9.7)
III 9 (30.0) 8 (25.8)
IV 15 (50.0) 15 (48.4)
Unknown 4 (13.3) 1 (3.2)
Type of cancer, n (%)a
NSCLC 8 (26.7) 6 (19.4)
CRC 4 (13.3) 4 (12.9)
Soft tissue sarcoma 4 (13.3) 4 (12.9)
Melanoma 3 (10.0) 0 (0.0)
Biliary tree 2 (6.7) 0 (0.0)
Bladder 0 (0.0) 3 (9.7)
Breast 0 (0.0) 2 (6.5)
Pleura 0 (0.0) 2 (6.5)
Any prior anticancer therapy, n (%)
Systemic chemotherapy 28 (93.3) 29 (93.5)
Surgery 16 (53.3) 19 (61.3)
Radiotherapy 19 (63.3) 15 (48.4)
Other 14 (46.7) 15 (48.4)
Abbreviations: CRC colorectal cancer, ECOG PS Eastern Cooperative
Oncology Group Performance Status, NSCLC non-small cell lung cancer
a In >5 % of patients
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with DLTs during the first cycle with the 350/75 dose combi-
nation of six patients, this appeared to be above the MTD. The
combination of volasertib 300 mg and cisplatin 100 mg/m2
was determined to be the MTD. Two of the six patients in the
extension cohort at the MTD experienced a DLT during cycle
1 (grade 3 blood creatinine increased [n=1]; grade 3 fatigue
[n=1]).
In the volasertib/carboplatin arm, no DLTs were observed
during the first treatment cycle in the first three cohorts tested
(100/AUC4, 100/AUC5, and 200/AUC5; Table 2). One of six
patients enrolled in the 300/AUC5 cohort experienced two
DLTs during the first treatment cycle (grade 4 thrombocyto-
penia and grade 4 neutropenia for ≥7 days). No additional
DLTs were observed and the dose was escalated to 300/AUC6.
One of the first six patients in the 300/AUC6 cohort experienced
a DLT during cycle 1 (grade 4 thrombocytopenia). With dose
escalation to 350/AUC5, two of three patients experienced DLTs
in cycle 1 (grade 4 thrombocytopenia [n=1]; grade 4
neutropenia for ≥7 days, grade 4 thrombocytopenia, grade 3
fatigue, grade 3 febrile neutropenia, grade 3 nausea, and grade
3 anorexia [n=1]). The dose of 350/AUC5 was, therefore,
considered above the MTD and the combination of volasertib
300 mg and carboplatin AUC6 was determined to be the
MTD. One patient in the next six patients in the extension
cohort at the MTD experienced a DLT (grade 4 thrombocyto-
penia) in cycle 1.
Safety
DLTs after the first cycle were experienced by a total of three
patients in the volasertib/cisplatin arm. Two patients treated
with 300/75 experienced DLTs: one had grade 4 neutropenia
for ≥7 days in cycle 3 and grade 3 febrile neutropenia in cycle
4, and a second experienced grade 4 neutropenia for ≥7 days
in cycle 3. One patient treated with 300/100 experienced grade 4
neutropenia for ≥7 days in cycle 4. No patients in the
volasertib/carboplatin arm experienced a DLT after the first
cycle.
All 30 patients in the volasertib/cisplatin arm had ≥1 AE
regardless of CTCAE grade and relatedness. All of the pa-
tients in this treatment arm also had ≥1 drug-related AE. The
most common drug-related AEs across the dose cohorts and
for all grades were anemia, neutropenia, leukopenia, nausea,
vomiting, and thrombocytopenia (Table 3). Drug-related
grade 3/4 AEs occurred in every dose cohort in the
volasertib/cisplatin arm and in 21 patients (70.0 %) overall.
The most common drug-related grade 3/4 AEs were
neutropenia, lymphopenia, leukopenia, fatigue, and
thrombocytopenia. Thirteen patients (43.3 %) had a total of
27 serious adverse events (SAEs) during the treatment period.
Of these, 12 drug-related SAEs experienced by seven patients
included nausea, vomiting, and increased blood creatinine
(two patients, 6.7 % for each event). Other drug-related
SAEs were single cases of anemia, neutropenia, febrile
neutropenia, pyrexia, tumoral hemothorax, and orthostatic
hypotension. There were no deaths in the volasertib/cisplatin
arm during treatment.
Two patients (6.7 %) in the volasertib/cisplatin arm
discontinued trial drug because of AEs: one patient in the
200/75 cohort had cisplatin discontinued because of a grade 2
hypersensitivity reaction during the sixth cycle, and one
patient in the 300/100 had both volasertib and cisplatin
discontinued after the first cycle because of a DLT of grade 3
increased blood creatinine. Six patients (20.0%) had a total of 10
AEs that led to dose reductions of one or both drugs. One
patient (33.3 %) in the 100/75 cohort had a reduction of
cisplatin only to 60 mg/m2 starting in cycle 4 following grade 3
Table 2 Overall summary of DLTs occurring in cycle 1 (treated set)
Dose cohorts N n with
DLTs
DLT
Volasertib (mg)/
Cisplatin
(mg/m2)
100/60 3 0 None
100/75 3 0 None
200/75 3 0 None
300/75 3 0 None
300/100a 6 1 Grade 4 neutropenia for
≥7 days
300/100b 6 2 Grade 3 increased blood
creatinine (n=1); grade 3
fatigue (n=1)
350/75 6 2 Grade 3 increased ALT (n=1);
grade 3 fatigue and
grade 4 neutropenia for
≥7 days (n=1)
Volasertib (mg)/
Carboplatin
(AUC)
100/4 3 0 None
100/5 3 0 None
200/5 3 0 None
300/5 6 1 Grade 4 thrombocytopenia
and grade 4 neutropenia
for ≥7 days
300/6a 6 1 Grade 4 thrombocytopenia
300/6b 7c 1 Grade 4 thrombocytopenia
350/5 3 2 Grade 4 thrombocytopenia
(n=1); grade 4
neutropenia for ≥7 days,
grade 4 thrombocytopenia,
grade 3 fatigue, grade 3
febrile neutropenia, grade 3
nausea, and grade 3
anorexia (n=1)
Abbreviations: ALT alanine aminotransferase, AUC area under the con-
centration versus time curve, DLTs dose-limiting toxicities, MTD maxi-
mum tolerated dose
a Defined as the MTD
bMTD cohorts were expanded to further characterize safety
c One patient was not evaluable for MTD and was replaced
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neutropenia. One patient (33.3 %) in the 300/75 cohort had
dose reductions of both drugs and was treated with 300/60
in cycle 5 and 200/60 in cycle 6 due to grade 4 neutropenia.
This patient continued treatment with volasertib for a total of
20 cycles. Three patients (25.0 %) in the 300/100 cohort had
a dose reduction to 200/75 in cycle 2 (grade 4 neutropenia
and grade 3 thrombocytopenia [n=1]; grade 3 fatigue [n=2]).
One patient (16.7%) in the 350/75 cohort had a dose reduction to
300/60 in cycle 2 due to grade 4 neutropenia, grade 3
thrombocytopenia, grade 3 fatigue, and grade 1 pyrexia.
All 31 patients in the volasertib/carboplatin arm had ≥1 AE
regardless of CTCAE grade and relatedness. Thirty patients
(96.8 %) in the volasertib/carboplatin arm had ≥1 drug-related
AE (Table 3). The most common drug-related AEs across the
dose cohorts were anemia, thrombocytopenia, leukopenia,
neutropenia, and lymphopenia. Drug-related grade ≥3 AEs
occurred in 23 patients (74.2 %) overall. The most common
drug-related grade ≥3 AEs were neutropenia, thrombocytope-
nia, anemia, and leukopenia. Eleven patients (35.5 %) had a
total of 37 SAEs during the treatment period. Of these, 13
drug-related SAEs experienced by three patients included
anemia, neutropenia, and thrombocytopenia (9.7 % with each
event), and single cases of decreased appetite, nausea, fatigue,
and febrile neutropenia. Two patients in the volasertib/
carboplatin arm (both in the 300/AUC6 cohort) died while
on treatment. One patient died of respiratory tract infection
and septic shock after seven cycles of volasertib and six cycles
of carboplatin (normal neutrophil count on the day of death),
and one patient died of neoplasm progression after 11 cycles
of volasertib and six cycles of carboplatin (during the follow-
up period after discontinuation for progression). Neither of the
fatal SAEs was considered to be drug related.
Four patients (12.9 %) in the volasertib/carboplatin arm
had a total of six AEs that led to dose reductions of one or
both drugs. One patient (16.7 %) in the 300/AUC5 cohort had
a dose reduction of both drugs and was treated with 200/AUC4
starting in cycle 2 due to grade 4 neutropenia and grade 4
thrombocytopenia. This patient continued treatment with
volasertib for a total of 14 cycles. Two patients (15.4 %) in
the 300/AUC6 cohort had dose reductions (dose reduction of
carboplatin only in one case). One patient was treated with
300/AUC4 starting in cycle 4 due to grade 3 thrombocytope-
nia; the second patient received 200/AUC4 starting in cycle 2
due to grade 4 thrombocytopenia (both dose reductions were
protocol violations; per protocol, these two patients should
have received 200/AUC5). One patient (33.3 %) in the 350/
AUC5 cohort was reduced to 300/AUC4 in cycle 2 due to
grade 4 neutropenia and grade 4 thrombocytopenia.
Pharmacokinetics
A total of 60 patients in the treated set were included in the
pharmacokinetic set. One patient from the volasertib/
carboplatin (300/AUC6) cohort was not included because
the administration date and/or time of volasertib dosing was
missing. Volasertib exhibited multi-exponential pharmacoki-
netic behavior with fast distribution after the end of infusion,
followed by several slower elimination phases in combination
with cisplatin (Fig. 1a) or carboplatin (Fig. 1b). Key pharma-
cokinetic parameters from both treatment arms were generally
comparable with a high volume of distribution, moderate total
plasma clearance and long t1/2 (Table 4). Dose-normalized
pharmacokinetic exposure parameters of volasertib were sim-
ilar with either cisplatin or carboplatin co-administration
(Table 4).
The area under the concentration-time curve in plasma over
the time interval from 0 extrapolated to infinity (AUC0–∞) of
CD 10899, volasertib’s primary metabolite, was approximate-
ly 20 % that of volasertib, independent of whether volasertib
was combined with cisplatin or carboplatin (Table 4).
CD 10899 showed similar pharmacokinetic behavior to
volasertib. The overall geometric mean (gMean) half-lives of
CD 10899 following intravenous infusion of volasertib were
similar in the cisplatin and carboplatin arms (Table 4).
Both cisplatin and carboplatin exhibited multi-exponential
disposition pharmacokinetics with a fast distribution phase
after the intravenous infusion (data not shown). Total platinum
plasma clearance was about 9.7 mL/min for cisplatin and
80.5 mL/min for carboplatin. Total platinum distributed in a
small volume of around 73.2 L with cisplatin and around
196.2 L with carboplatin. Mean apparent half-lives of total
platinum were 88.9 hours for cisplatin and 40.3 hours for
carboplatin.
Antitumor activity
Tumor response according to RECISTwas evaluable in 26 of
the 30 patients in the volasertib/cisplatin arm (Table 5). Four
patients (13.3 %) did not have any post-baseline tumor assess-
ments and were not evaluable for response. Best overall re-
sponse (BOR) was PRs in two patients (6.7%). One responder
(100/75 cohort) was a 50-year-old female patient with an un-
differentiated follicular dendritic reticulum cell sarcoma of the
palatine tonsil. At screening, she had metastases in the lung.
Prior to enrollment, she had received combination cyclophos-
phamide, vincristine, doxorubicin, and prednisone (BOR was
PR). In this study, she received six cycles of cisplatin and
15 cycles of volasertib and achieved a PR after 43 days from
treatment initiation and a PFS of 340 days. The second re-
sponder (300/75 cohort) was a 42-year-old female patient with
a well differentiated follicular dendritic reticulum cell retro-
peritoneal sarcoma. She had metastases in the bone, liver, and
muscles at screening. She had previously undergone surgery
followed by combination cyclophosphamide, vincristine,
doxorubicin, and prednisolone (BOR was PD). She received
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six cycles of cisplatin and 20 cycles of volasertib and achieved
a PR after 78 days and a PFS of 436 days.
An additional 11 patients (36.7 %) in the volasertib/
cisplatin arm achieved SD including the following tumor
types: non-small cell lung cancer (NSCLC; n=3), colorectal
cancer (CRC; n=3), and melanoma (n=2). Disease control
(defined as a BOR of SD, PR, or complete response) was
achieved in 13 patients (43.3 %), with a median duration (de-
fined as the time from the start of study treatment to the time of
disease progression or death) of 155.0 (range, 97–436) days.
Median PFS for all patients across the cohorts was 93.5
(range, 1–436) days.
In the volasertib/carboplatin arm, tumor response was
evaluable in 26 of the 31 patients (Table 5). Four patients
(12.9 %) did not have any post-baseline tumor assessments
and were not evaluable for response, and one patient (3.2 %)
had a non-evaluable tumor at baseline. BOR was PRs in two
patients (6.5 %). One responder (300/AUC5 cohort) was a
65-year-old male patient with a poorly differentiated hypo-
pharynx carcinoma. He had metastases in the lung at screening.
Prior to enrollment, he had previously received combination
chemotherapy with cisplatin and fluorouracil, followed by
combination carboplatin and fluorouracil (BOR was PR) and
Fig. 1 gMean plasma
concentration-time profiles of
total volasertib after intravenous
infusion of volasertib in
combination with (a) cisplatin or
(b) carboplatin (semi-log scale).
Abbreviations: AUC area under
the concentration versus time
curve, gMean geometric mean
Table 4 Overall summary of non-compartmental pharmacokinetic
parameters of volasertib combined with cisplatin or carboplatin
Volasertib/cisplatin Volasertib/carboplatin
n gMean gCV (%) n gMean gCV (%)
Volasertib
AUC0-∞,norm
([ng·h/mL]/mg)
28 16.7 30.4 28 19.3 26.6
Cmax,norm
([ng/mL]/mg)
30 1.29 61.5 29 1.40 46.7
t1/2 (h) 28 137 26.0 28 166 32.0
CL (mL/min) 28 999 30.4 28 865 26.6
Vss (L) 28 6780 53.6 28 7550 44.5
CD 10899a
RAUC0-∞,M/P (%) 26 21.9 33.9 26 18.6 27.1
t1/2 (h) 26 134 28.4 27 152 33.2
Abbreviations: AUC0-∞ area under the concentration-time curve in
plasma over the time interval from 0 extrapolated to infinity, CL total
clearance, Cmax maximum measured concentration in plasma, gCV
geometric coefficient of variation, gMean geometric mean, norm dose
normalized, RAUC0-∞,M/P AUC ratio metabolite CD 10899/volasertib,
t1/2 terminal half-life, Vss apparent volume of distribution at steady state
aMetabolite of volasertib
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sequential single-agent therapy with methotrexate (BOR was
SD), docetaxel (BOR was SD), and zalutumumab. He received
six cycles of carboplatin and 14 cycles of volasertib and
achieved a PR 50 days after treatment initiation and a PFS of
331 days. The second responder (300/AUC6 cohort) was a 60-
year-old male patient with squamous NSCLC. He had metas-
tases in the lung and was stage IV at screening. He had previ-
ously received a platinum doublet with cisplatin and
gemcitabine (BOR was SD), followed by sequential single-
agent therapy with pemetrexed (BOR was PD), docetaxel
(BOR was PD), and an investigational survivin inhibitor
(BORwas PD). He received six cycles of carboplatin and 11 cy-
cles of volasertib, and achieved a PR after 37 days and a PFS of
243 days.
An additional six patients (19.4 %) in the volasertib/
carboplatin arm achieved SD including two patients with
NSCLC. Disease control was achieved in eight patients
(25.8 %), with a median (range) duration of disease control
overall of 183.5 (100–331) days. Median (range) PFS for all
patients across the cohorts was 43.0 (1–331) days.
Discussion
This was a phase I, open-label, dose-escalation study designed
to determine the MTD, DLTs, safety, pharmacokinetics, and
antitumor effects of the Plk inhibitor volasertib administered
in combination with cisplatin or carboplatin in patients with
advanced/metastatic solid tumors. The MTDs were determined
to be volasertib 300mg plus cisplatin 100mg/m2 and volasertib
300 mg plus carboplatin AUC6 (limited to a maximum dose of
900 mg) administered on day 1 of a 3-week cycle. This MTD
for volasertib combination therapy is the same as the recom-
mended dose for volasertib monotherapy in solid tumors [13].
The most frequently observed DLTs were hematologic
changes, which were expected based on previous experience
with single-agent volasertib [13] and single-agent platinums
[21, 22]. The AEs observed in this study were primarily a result
of hematopoietic suppression from both agents in each combi-
nation. No additive effects were detected, indicating that each
drug (volasertib, cisplatin, or carboplatin) can be administered
in combination at the recommended maximum single-agent
doses without an increase in AEs or unexpected safety findings.
The higher frequency of hematologic AEs at volasertib doses
exceeding 300 mgmay be related to volasertib more than to the
combination partner since comparable AE frequencies were
observed with volasertib 300mg combined with different doses
of cisplatin or carboplatin. However, because separate causal
assessments for volasertib and platinumwere not performed, all
observed AEs should be related to the combination and were
not necessarily attributable to volasertib alone.
The current study of volasertib in combination with cisplat-
in or carboplatin showed no influence of cisplatin or
carboplatin on the pharmacokinetics or metabolism of
volasertib. As shown with monotherapy [13], volasertib ex-
hibited multi-exponential pharmacokinetic behavior with ex-
tensive distribution into deep body compartments, a long t1/2
and moderate clearance. Based on a comparison with histori-
cal data for volasertib monotherapy, platinum drugs showed
no influence on the pharmacokinetics of volasertib. Both
cisplatin and carboplatin (co-administered with volasertib),
measured as total platinum, showed multi-exponential
pharmacokinetic behavior and the major pharmacokinetic
parameters (maximum measured concentration in plasma
[Cmax], AUC, and clearance) were comparable to the published
data on monotherapy of the respective compounds [23–25].
In this population of patients with advanced/metastatic solid
tumors, volasertib in combination with cisplatin or carboplatin
showed encouraging signs of antitumor activity. Of 26 evaluable
patients treated with volasertib/cisplatin, two had a PR and 11
achieved SD as best response. In combination with carboplatin,
two of 26 evaluable patients had a PR and six achieved SD. One
interesting finding was the activity observed in two female
patients with follicular dendritic reticulum cell sarcoma, an
orphan disease with sensitivity to drugs used for treatment of
mesenchymal tumors and lymphoma. Both patients achieved
durable PRs with volasertib/cisplatin treatment, with decreases
in tumor size that persisted after completion of the maximum
number of cycles with platinum.
It is generally acknowledged that novel agents/regimens
for the treatment of patients with advanced/metastatic solid
Table 5 Antitumor activity in evaluable patients
Volasertib/cisplatin
(n=30)
Volasertib/carboplatin
(n=31)
Disease control rate, n (%) 13 (43.3) 8 (25.8)
PR confirmed 2 (6.7)a 2 (6.5)b
SD 11 (36.7)c 6 (19.4)d
PD 13 (43.3) 18 (58.1)
Missinge 4 (13.3) 4 (12.9)
Not evaluable 0 (0) 1 (3.2)
Median PFS, days (range) 93.5 (1–436) 43.0 (1–331)
Abbreviations: CRC colorectal cancer, NSCLC non-small cell lung can-
cer, PD progressive disease, PFS progression-free survival, PR partial
response, SD stable disease
a Tumor types: follicular dendritic reticulum cell carcinoma of the palatine
tonsil (n=1), follicular dendritic reticulum cell retroperitoneal sarcoma
(n=1)
b Tumor types: hypopharynx carcinoma (n=1), NSCLC (n=1)
c Tumor types: NSCLC (n=3), CRC (n=3), melanoma (n=2), bladder
cancer (n=1), breast cancer (n=1), endocrine cancer (n=1)
d Tumor types: NSCLC (n=2), biliary tree cancer (n=1), liver cancer
(n=1), pancreatic cancer (n=1), pleural cancer (n=1)
eMissing indicates that there was no tumor assessment post-baseline and
response status could not be assessed
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tumors are an unmet need. This trial demonstrated a generally
acceptable safety profile and antitumor activity for volasertib
in combination with cisplatin or carboplatin in patients with
advanced/metastatic solid tumors. These data suggest that the
investigation of volasertib for the treatment of patients with
advanced/metastatic solid tumors, in particular, in combina-
tion with cytotoxic agents like platinums, is warranted.
Additional studies focusing on predictive biomarkers would
be beneficial to better understand the role of Plk inhibition in
tumor development and anticancer therapy.
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